摘要
目的探讨替吉奥联合放疗治疗局部晚期胃癌的疗效及安全性。方法 84例局部晚期胃癌患者,随机分为试验组(43例)与对照组(41例)。对照组采用三维适形放疗,1.8～2.0 Gy/次,5次/周,总剂量45～50 Gy。试验组在三维适形放疗基础上联合口服替吉奥化疗,剂量40～60 mg/m2,2次/d,口服5 d,休息2 d,7 d为1周期,共进行5个周期。观察比较两组患者临床疗效及不良反应。结果试验组缓解率为69.8%,对照组缓解率为41.4%,两组差异有统计学意义(P<0.05)。试验组1年生存率(53.5%)高于对照组(46.9%),但差异无统计学意义(P>0.05)。试验组恶心呕吐(74.4%)及白细胞下降(81.4%)发生率明显高于对照组(39.0%和48.8%),差异有统计学意义(P<0.05);而两组在肝功能损害(13.9%vs. 9.8%)、肾功能损害(7.0%vs.4.9%)、腹泻(39.5%vs. 39.0%)方面比较,差异无统计学意义(P>0.05)。结论替吉奥联合放疗治疗局部晚期胃癌具有良好的临床疗效,不良反应可耐受。
Objective To discuss the efficacy and toxicity of S-1 combined with radiotherapy for locally advanced gastric cancer. Methods Totally 84 patients with locally advanced gastric cancer were randomly divided into experimental group(43 patients) and control group(41 patients). The control group only received 3-dimensional conformal radiation therapy(3 D-CRT), but the experimental group was given S-1 chemotherapy combined with 3 D-CRT. The patients took S-1 40～60 mg/m2,twice per day for five days, two days off, and a total of 5 cycles were implemented. Then clinical effect and toxicity were observed and compared. Results The overall remission rates in the experimental group and the control group were 69.8% and 41.4% respectively(P<0.05). The 1-year survival rate in the experimental group(53.5%) was higher than that in the control group(46.9%), but there was no significant difference(P>0.05). The incidence of nausea and vomiting(74.4%) and leukopenia(81.4%) in the experimental group were significantly higher than those in the control group(39.0%and 48.8%). There were no significant differences in liver function damage(13.9% vs. 9.8%), renal function impairment(7.0% vs. 4.9%) and diarrhea(39.5% vs. 39.0%) between the two groups(P>0.05). Conclusions S-1 combined with radiotherapy has good clinical effects and tolerable toxicity in the treatment of patients with locally advanced gastric cancer.
出处
《慢性病学杂志》
2018年第11期1481-1483,1488,共4页
Chronic Pathematology Journal
关键词
胃癌
三维适形放疗
替吉奥
同步放化疗
Gastric cancer
Three-dimensional conformal radiation therapy
S-1
Chemoradiotherapy
